n,n-dimethylarginine has been researched along with glucagon-like peptide 1 in 3 studies
| Studies (n,n-dimethylarginine) | Trials (n,n-dimethylarginine) | Recent Studies (post-2010) (n,n-dimethylarginine) | Studies (glucagon-like peptide 1) | Trials (glucagon-like peptide 1) | Recent Studies (post-2010) (glucagon-like peptide 1) |
|---|---|---|---|---|---|
| 2,216 | 228 | 1,221 | 9,484 | 1,208 | 6,374 |
| Protein | Taxonomy | n,n-dimethylarginine (IC50) | glucagon-like peptide 1 (IC50) |
|---|---|---|---|
| Glucagon-like peptide 1 receptor | Homo sapiens (human) | 0.0051 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Anders, S; Forst, T; Michelson, G; Mitry, M; Pfützner, A; Ratter, F; Weber, MM; Wilhelm, B | 1 |
| Fukami, K; Ishibashi, Y; Maeda, S; Matsui, T; Nishino, Y; Ojima, A; Takeuchi, M; Yamagishi, S | 1 |
| Bełtowski, J; Czechowska, G; Fornal, E; Góralczyk, A; Korolczuk, A; Kozub, A; Marzec-Kotarska, B; Nikolaichuk, H; Pradiuch, A; Stachniuk, A; Trzpil, A; Wójcicka, G | 1 |
1 trial(s) available for n,n-dimethylarginine and glucagon-like peptide 1
| Article | Year |
|---|---|
Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function.
Topics: Adult; Aged; Arginine; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; E-Selectin; Endothelium, Vascular; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Microcirculation; Middle Aged; Plasminogen Activator Inhibitor 1; Proinsulin; Prospective Studies | 2012 |
2 other study(ies) available for n,n-dimethylarginine and glucagon-like peptide 1
| Article | Year |
|---|---|
Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression.
Topics: Animals; Arginine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drug Evaluation, Preclinical; Exenatide; Gene Expression Regulation, Enzymologic; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycation End Products, Advanced; Humans; Hypertrophy; Hypoglycemic Agents; Kidney; Kidney Glomerulus; Kidney Tubules; Macrophages; Male; Peptides; Protein-Arginine N-Methyltransferases; Rats; Rats, Wistar; Reactive Oxygen Species; Receptor for Advanced Glycation End Products; Receptors, Glucagon; Receptors, Immunologic; Repressor Proteins; RNA, Messenger; Venoms | 2013 |
The effect of exenatide (a GLP-1 analogue) and sitagliptin (a DPP-4 inhibitor) on asymmetric dimethylarginine (ADMA) metabolism and selected biomarkers of cardiac fibrosis in rats with fructose-induced metabolic syndrome.
Topics: Amidohydrolases; Animals; Arginine; Biomarkers; Chromatography, Liquid; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Fibrosis; Fructose; Glucagon-Like Peptide 1; Hypoglycemic Agents; Metabolic Syndrome; Nitric Oxide; Protease Inhibitors; Rats; Sitagliptin Phosphate; Tandem Mass Spectrometry | 2023 |